At the recent American Society of Hematology annual meeting, researchers presented preclinical data examining how transdifferentiation between hematopoietic lineages -- driven by LMO2 expression and ...
As part of consolidation therapy, patients may receive allogenic hematopoietic stem cell transplantation (HCT). HCT involves the replacement of a patient's normal source of bone marrow cells by ...
A new treatment using genome-edited immune cells, developed by scientists at UCL (University College London) and Great Ormond Street Hospital (GOSH), has shown promising results in helping children ...
B-cell Acute Lymphoblastic Leukaemia (B-ALL) is a life-threatening and highly aggressive form of blood cancer. It is the most common childhood cancer, making up 35% of paediatric cancer cases, but it ...
U.S. FDA Grants to Wugen’s WU-CART-007 Breakthrough Therapy Designation for Treatment of Relapsed or Refractory T Cell Acute Lymphoblastic Leukemia / T Cell Lymphoblastic Lymphoma -- Breakthrough ...
Older patients (≥ 55 to60 years) with B-cell acute lymphoblastic leukemia (B-ALL) have high-risk cytogenetic and molecular abnormalities, as well as Philadelphia chromosome (Ph)-positive and Ph-like ...
An expert discusses IL-18-armored CAR T cells for adults with relapsed B-cell leukemia, showing complete remissions with manageable side effects. In an onsite interview with CURE at the 2025 ASH ...
Emily Taylor said her 7-year-old son Jerett, who goes by Rett, was first diagnosed with T-cell acute lymphoblastic leukemia ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results